Galen, an Almac Group Company, Announces Completion of Multi-Million Pound POA Pharma Acquisition

Almac集团公司Galen宣布以百万英镑收购医疗保健公司POA Pharma

2020-01-10 08:30:10 BioSpace


Craigavon, N.I., 8 Jan 2020 - Galen, a member of the Almac Group and privately owned global pharmaceutical sales and marketing company, today announced the completion of a multi-million pound acquisition and takeover of boutique healthcare company, POA Pharma. The move enables Galen to significantly expand its global reach and product portfolio in exciting new therapy areas, such as rare metabolic disease. Headquartered in Sweden, with additional facilities located across the Nordic region and North America, POA Pharma currently represents 16 producers from 10 countries and retains a strong portfolio of products and an extensive network worldwide. Galen first signed a distribution agreement with POA Pharma in April 2016, allowing the company to market and sell POA Pharma’s metabolic product portfolio in the UK and Ireland. The acquisition is an extremely significant new phase of Galen’s growth, as it extends its global footprint into the Nordic territory and Northern Europe. As part of the takeover, Simon Lawrence, who has held various senior management positions with Galen over 33 years, has been appointed Commercial Director – Nordics and will be based at the POA facility in Copenhagen. He will oversee operations in the region and grow the team to reflect demand in line with the global Galen strategy. Simon Lawrence commented: “Galen’s long-heritage and expertise in delivering valued medicines to the people that need them most, coupled with POA Pharma’s important portfolio, means we now have the opportunity to improve the lives of more people affected by a variety of diseases on a truly global scale. Particularly for the underserved, rare, phenylketonuria (PKU) population, who have limited treatment options available to them, today’s completion is a welcome step towards better access to life-saving nutritional therapies across Galen’s extensive distribution network and beyond.” Dr Dennise Broderick, President & Managing Director Galen added: "This acquisition is highly complementary to our established business and marks a key milestone in our strategic global growth plans. The founders of POA have created a highly successful business and we look forward to incorporating and growing the reputable company further as part of the Galen organisation. This acquisition will enable Galen to offer a wider range of products to our customers, healthcare professionals and patients around the world." Notes to editors About POA POA Pharma is a market oriented Boutique Healthcare Company present in 9 competence areas with offices in Denmark, Finland, Norway, Sweden and US. The home market is the Nordic countries were POA represents 16 pharmaceutical producers from 10 countries. Our export is based on POA proprietary products, classified as food for specific medical purposes, products that are sold in more than 40 countries. About Galen Established in 1968, Galen is a privately owned pharmaceutical sales and marketing company, headquartered in Craigavon (Northern Ireland), with products in therapy areas including gastroenterology, urology, female health, pain management and mental health. As a subsidiary of Galen Limited, Galen US also has a growing presence in select conditions requiring topical anaesthesia and Central Nervous System disorders. The company plans to continue expanding its portfolio with selected specialty products on an international basis. By combining innovation in product development with competitive pricing, Galen aims to work in partnership with healthcare professionals and patients to create real, long-term value. Visit: About Almac Group Galen is a member of the Almac Group. The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across, and beyond, the drug development lifecycle to the pharmaceutical and biotech sectors globally. Almac’s innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture, product development and marketing. The international company is a privately owned organisation that has grown organically over the past five decades and now employs over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia. Almac has a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.
Galen , Almac 集团的成员,私人拥有的全球医药销售和营销公司,今天宣布完成数百万英镑收购和收购精品医疗保健公司 POA Pharma 。这一举措使 Galen 能够在令人兴奋的新治疗领域(如罕见的代谢疾病)显著扩大其全球范围和产品组合。 POA Pharma 总部位于瑞典,在北欧地区和北美拥有更多的设施,目前代表来自10个国家的16家生产商,在全球范围内拥有强大的产品组合和广泛的网络。Galen 于2016年4月首次与 POA Pharma 签订经销协议,允许公司在英国和爱尔兰市场销售 POA Pharma 的代谢产品组合。此次收购是 Galen 增长的一个极其重要的新阶段,因为它将全球业务扩展到北欧地区和北欧。 作为收购的一部分,西蒙•劳伦斯( Simon Lawrence )已被任命为北欧商业总监,并将在哥本哈根的 POA 工厂工作。劳伦斯在加伦担任了33年多的高级管理职位。他将监督该地区的运营,并根据全球 Galen 战略发展团队以反映需求。 西蒙•劳伦斯( Simon Lawrence )表示:“ Galen 在向最需要药物的人提供有价值药物方面的长期传统和专业知识,加上 POA Pharma 的重要产品组合,意味着我们现在有机会在真正的全球范围内改善更多受各种疾病影响的人的生活。特别是对于服务不足、稀有的苯酮尿症( PKU )人群,他们有有限的治疗选择,今天的完成是一个值得欢迎的步骤,以更好地获得拯救生命的营养疗法,在 Galen 的广泛分布网络和更远的地方。” Galen 总裁兼董事总经理 Dennise Broderick 博士补充道:“本次收购对我们已建立的业务高度互补,标志着我们战略全球增长计划的一个关键里程碑。POA 的创始人创造了一个非常成功的业务,我们期待着进一步合并和发展信誉良好的公司作为 Galen 组织的一部分。此次收购将使 Galen 能够向我们的客户、医疗保健专业人员和世界各地的患者提供更广泛的产品。” 编辑须知 关于 POA POA Pharma 是一家以市场为导向的 Boutique Healthcare Company ,在丹麦、芬兰、挪威、瑞典和美国设有办事处。本土市场是北欧国家, POA 代表了来自10个国家的16家制药商。我们的出口以 POA 专有产品为基础,分类为特定医疗用途的食品,产品销往40多个国家。 关于 Galen Galen 公司成立于1968年,是一家私人拥有的医药销售和营销公司,总部位于 Craigavon (北爱尔兰),产品涉及治疗领域,包括胃肠病学、泌尿学、女性健康、疼痛管理和精神健康。 作为 Galen Limited 的子公司, Galen US 在需要局部麻醉和中枢神经系统疾病的特定条件下也越来越多地存在。该公司计划继续扩大其在国际上选定的专业产品组合。通过将产品开发的创新与具有竞争力的定价相结合, Galen 旨在与医疗保健专业人员和患者合作,创造真正的长期价值。访问: www.galen-pharma 。com 关于 Almac 集团 Galen 是 Almac 集团的成员。Almac 集团是一家成熟的合同开发和制造组织,为全球制药和生物技术部门提供药品开发生命周期内外的广泛综合服务。 Almac 的创新服务范围从研发、生物标志物发现开发和商业化、原料药(API)制造、制剂开发、临床试验供应、 IRT ( IVRS / IWRS )到商业化生产、产品开发和营销。 这家国际公司是一家私人拥有的组织,在过去50年里实现了有机增长,目前在包括欧洲、美国和亚洲在内的18家工厂拥有5600多名高技能员工。 Almac 拥有超过50年的卓越客户服务的全球声誉,在药物开发生命周期内提供专业知识,并为我们的每个客户提供量身定制的解决方案。